Sökning: WFRF:(Wetterholm AL)
> (2001) >
A 1-year, randomize...
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
-
- Winblad, B (författare)
- Karolinska Institutet
-
Engedal, K (författare)
-
Soininen, H (författare)
-
visa fler...
-
Verhey, F (författare)
-
Waldemar, G (författare)
-
- Wimo, A (författare)
- Karolinska Institutet
-
Wetterholm, AL (författare)
-
Zhang, R (författare)
-
Haglund, A (författare)
-
Subbiah, P (författare)
-
visa färre...
-
(creator_code:org_t)
- 2001-08-14
- 2001
- Engelska.
-
Ingår i: Neurology. - : Ovid Technologies (Wolters Kluwer Health). - 0028-3878 .- 1526-632X. ; 57:3, s. 489-495
- Relaterad länk:
-
http://kipublication...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective: To evaluate the long-term clinical efficacy and safety of donepezil versus placebo over 1 year in patients with mild to moderate AD.Methods: Patients (n = 286; mean age, 72.5 years) with possible or probable AD from five Northern European countries were randomized to receive either donepezil (n = 142; 5 mg/day for 28 days, followed by 10 mg/day) or placebo (n = 144) for 1 year.Results: The study was completed by 66.9% of the donepezil- and 67.4% of the placebo-treated patients. The benefit of donepezil over placebo was demonstrated by the Gottfries-Bråne-Steen (a global assessment for rating dementia symptoms) total score at weeks 24, 36, and 52 (p < 0.05) and at the study end point (week 52, last observation carried forward; p = 0.054). Advantages of donepezil over placebo were also observed in cognition and activities of daily living (ADL) assessed by the Mini-Mental State Examination at weeks 24, 36, and 52, and the end point (p < 0.02) and by the Progressive Deterioration Scale at week 52 and the end point (p < 0.05). Adverse events (AE) were recorded for 81.7% of donepezil- and 75.7% of placebo-treated patients, with 7% of donepezil- and 6.3% of placebo-treated patients discontinuing because of AE. Treatment response to donepezil was not predicted by APOE genotype or sex in this population.Conclusion: As the first 1-year, multinational, double-blinded, placebo-controlled study of a cholinesterase inhibitor in AD, these data support donepezil as a well tolerated and effective long-term treatment for patients with AD, with benefits over placebo on global assessment, cognition, and ADL.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Winblad, B
-
Engedal, K
-
Soininen, H
-
Verhey, F
-
Waldemar, G
-
Wimo, A
-
visa fler...
-
Wetterholm, AL
-
Zhang, R
-
Haglund, A
-
Subbiah, P
-
visa färre...
- Artiklar i publikationen
-
Neurology
- Av lärosätet
-
Karolinska Institutet